Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Buy Rating from Analysts at Canaccord Genuity

Share on StockTwits

Equities research analysts at Canaccord Genuity initiated coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a report issued on Tuesday, October 16th, The Fly reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity’s price objective points to a potential upside of 17.51% from the stock’s previous close.

A number of other brokerages also recently issued reports on YMAB. Cowen restated a “buy” rating on shares of Y-mAbs Therapeutics in a research report on Tuesday, October 16th. BTIG Research began coverage on shares of Y-mAbs Therapeutics in a research report on Tuesday, October 16th. They issued a “buy” rating and a $35.00 price target on the stock.

Shares of NASDAQ YMAB traded down $0.26 during midday trading on Tuesday, reaching $25.53. The stock had a trading volume of 28,886 shares, compared to its average volume of 157,231. Y-mAbs Therapeutics has a twelve month low of $18.00 and a twelve month high of $31.00.

In related news, CEO Moller San Pedro Claus Juan acquired 31,250 shares of the stock in a transaction dated Tuesday, September 25th. The stock was bought at an average price of $16.00 per share, for a total transaction of $500,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James Healy acquired 500,000 shares of the stock in a transaction dated Friday, September 21st. The stock was bought at an average price of $16.00 per share, with a total value of $8,000,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 961,424 shares of company stock worth $15,382,784 in the last 90 days.

Several large investors have recently added to or reduced their stakes in YMAB. JPMorgan Chase & Co. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $798,000. Alliancebernstein L.P. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $8,632,000. BlackRock Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $398,000. Artal Group S.A. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $3,984,000. Finally, FMR LLC bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $32,686,000.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Story: How to Invest in Growth Stocks

The Fly

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply